OXY trims debt by $6.8 billion in 10 months, slashing interest costs and boosting flexibility for shareholder returns.
Vous n'êtes pas connecté
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
OXY trims debt by $6.8 billion in 10 months, slashing interest costs and boosting flexibility for shareholder returns.
Malaria remains a major barrier to Africa’s development, with nearly 600,000 deaths annually, mostly among children under five, and an estimated $16...
Malaria remains a major barrier to Africa’s development, with nearly 600,000 deaths annually, mostly among children under five, and an estimated $16...
By Lakshmy Ramakrishnan Biotechnology is a critical emerging technology holding significant potential in addressing various challenges,...
The development of novel anti─infectives requires a multi─pronged approach. We must explore new avenues for drug discovery, targeting novel...
As with all things in life, there’s initial fanfare, which eventually tapers into a more realistic, even somewhat sobering outlook. It’s human...
CBAM, a policy tool designed to prevent "carbon leakage" – where companies move production to countries with laxer environmental regulations to...
CBAM, a policy tool designed to prevent "carbon leakage" – where companies move production to countries with laxer environmental regulations to...
Business Wire India Monetate’s Real-Time Personalization Unites with SiteSpect’s Zero-Flicker Testing to Optimize Digital Experiences with...
Business Wire India Monetate’s Real-Time Personalization Unites with SiteSpect’s Zero-Flicker Testing to Optimize Digital Experiences with...